Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Virologic Failure and Emergent Integrase Strand Transfer Inhibitor Drug Resistance With Long-Acting Cabotegravir for HIV Treatment: A Meta-analysis

Clinical Infectious Diseases(2024)10.1093/cid/ciae631Source: DataRank Database

Virologic Failure and Emergent Integrase Strand Transfer Inhibitor Drug Resistance With Long-Acting Cabotegravir for HIV Treatment: A Meta-analysis is a research paper published in Clinical Infectious Diseases (2024). On theSindex it has a DataRank of 0. It has been cited 23 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access23 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 3.66)OA: hybridTopics (47)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (5)

Cameron T. Nutt,Mark J. Siedner ORCID,Suzanne M. McCluskey ORCID,Andrew Hill ORCID,Andrea Perez Navarro ORCID

Live enrichment

PubMed:39724249 PMC:PMC12448610 OpenAlex:https://openalex.org/W4405816081

World Health Organization

Grant: 2024_MV_001

National Institutes of Health

Grant: T32 AI007387

National Institutes of Health

Grant: K24 HL166024

National Institutes of Health

Grant: K23 AI143470

FWCI

3.66

Citation Percentile

0.9%

Citation Trend

2025

2026

hybridLicense: cc-by-nc-nd

journalhttps://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciae631/61280820/ciae631.pdf

publisherhttps://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciae631/61280820/ciae631.pdf

publisherhttps://academic.oup.com/cid/article-pdf/81/2/274/61280820/ciae631.pdf

journalhttps://doi.org/10.1093/cid/ciae631

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39724249

Fields of Study

HIV/AIDS drug development and treatmentHIV/AIDS Research and InterventionsPharmaceutical Quality and CounterfeitingMedicineHumansHIV InfectionsPyridonesDrug Resistance, ViralHIV Integrase InhibitorsRilpivirineTreatment FailureHIV-1Anti-HIV AgentsViral LoadDiketopiperazines

MeSH Terms

RilpivirineHumansPyridonesHIV-1HIV InfectionsTreatment FailureAnti-HIV AgentsHIV Integrase InhibitorsViral LoadDrug Resistance, ViralDiketopiperazines

Keywords

DolutegravirMedicineInternal medicineRegimenMeta-analysisDrug resistanceDosingViral loadHIV drug resistanceRilpivirineRaltegravirViremiaConfidence intervalPharmacologyHuman immunodeficiency virus (HIV)VirologyAntiretroviral therapyBiologyHIVCabotegravirIntegrase Strand Trasfer Inhibitors

Sustainable Development Goals

SDG 0: Good health and well-being